Menlo Park-based SRI International has received a $6.3 million grant from the National Institute of Mental Health to study a new product involved in brain imaging and the treatment of mental disorders, the company announced Oct. 5.

Among other things, the company will determine whether a new type of binding molecule can be administered to people for use in positron emission topography (PET), magnetic resonance imaging (MRI), and other types of brain scans, SRI said in a press release.